What do systematic reviews say?

Summary of findings: intranasal steroids plus oral antibiotic vs control plus antibiotic

The review found no eligible studies for this question.

• Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intranasal steroids plus oral antibiotic vs control plus antibiotic

• Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children 2011 · Cochrane Headline outcomes only
  no estimate extracted
  39 participants
  Moderate

Summary of findings: intranasal steroids plus oral antibiotic vs control plus antibiotic

• Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 59 participants
  GRADE not reported

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Summary of findings ‐ Hydroxyurea and phlebotomy showed no clear difference in death during the study (all deaths) compared with transfusion and chelation (low certainty).

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  RR 0.99 [0.06, 15.42]
  2 studies · 254 participants
  Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 254 participants
  Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 254 participants
  Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

The review found no eligible studies for this question.

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 254 participants
  Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Summary of findings ‐ Hydroxyurea and phlebotomy may leads to higher pain alteration: proportion experiencing serious VOC or… compared with transfusion and chelation (low certainty).

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  RR 3.37 [1.59, 7.11]
  2 studies · 254 participants
  Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 254 participants
  Moderate